253 related articles for article (PubMed ID: 29705980)
1. Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis.
Suma S; Sakata-Yanagimoto M; Nguyen TB; Hattori K; Sato T; Noguchi M; Nannya Y; Ogawa S; Watanabe R; Fujimoto M; Nakamura N; Kusakabe M; Nishikii H; Kato T; Chiba S
Int J Hematol; 2018 Oct; 108(4):447-451. PubMed ID: 29705980
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow.
Sadigh S; DeAngelo DJ; Garcia JS; Hasserjian RP; Hergott CB; Lane AA; Lovitch SB; Lucas F; Luskin MR; Morgan EA; Pinkus GS; Pozdnyakova O; Rodig SJ; Shanmugam V; Tsai HK; Winer ES; Zemmour D; Kim AS
Mod Pathol; 2024 Jan; 37(1):100352. PubMed ID: 37839675
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.
Khanlari M; Yin CC; Takahashi K; Lachowiez C; Tang G; Loghavi S; Bah I; Wang W; Konoplev S; Medeiros LJ; Pemmaraju N; Khoury JD; Wang SA
Leukemia; 2022 May; 36(5):1343-1350. PubMed ID: 35279700
[TBL] [Abstract][Full Text] [Related]
4. Srsf2
Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
[TBL] [Abstract][Full Text] [Related]
5. Mutated ZRSR2 and CUL3 accelerate clonal evolution and confer venetoclax resistance via RAS signaling pathway in blastic plasmacytoid dendritic cell neoplasm.
Fukuchi K; Koyama D; Takada M; Mori H; Hayashi K; Asano N; Sato Y; Fukatsu M; Takano M; Takahashi H; Shirado-Harada K; Kimura S; Yamamoto T; Ikezoe T
Int J Hematol; 2023 Oct; 118(4):489-493. PubMed ID: 37029861
[TBL] [Abstract][Full Text] [Related]
6. Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review.
Ding Y; Yang J; Lindsey K
Diagn Cytopathol; 2021 Feb; 49(2):E80-E83. PubMed ID: 32852895
[TBL] [Abstract][Full Text] [Related]
7. Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.
Dang X; Zhou D; Meng L; Bi L
J Int Med Res; 2021 Feb; 49(2):300060520982667. PubMed ID: 33530792
[TBL] [Abstract][Full Text] [Related]
8. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.
Jardin F; Ruminy P; Parmentier F; Troussard X; Vaida I; Stamatoullas A; Leprêtre S; Penther D; Duval AB; Picquenot JM; Courville P; Capiod JC; Tilly H; Bastard C; Marolleau JP
Br J Haematol; 2011 May; 153(3):413-6. PubMed ID: 21275969
[No Abstract] [Full Text] [Related]
9. Genomics of chronic neutrophilic leukemia.
Maxson JE; Tyner JW
Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
[TBL] [Abstract][Full Text] [Related]
10. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract][Full Text] [Related]
11. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.
Batta K; Bossenbroek HM; Pemmaraju N; Wilks DP; Chasty R; Dennis M; Milne P; Collin M; Beird HC; Taylor J; Patnaik MM; Cargo CA; Somervaille TCP; Wiseman DH
Leukemia; 2021 Nov; 35(11):3299-3303. PubMed ID: 33833384
[No Abstract] [Full Text] [Related]
12. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.
Alayed K; Patel KP; Konoplev S; Singh RR; Routbort MJ; Reddy N; Pemmaraju N; Zhang L; Shaikh AA; Aladily TN; Jain N; Luthra R; Medeiros LJ; Khoury JD
Am J Hematol; 2013 Dec; 88(12):1055-61. PubMed ID: 23940084
[TBL] [Abstract][Full Text] [Related]
13. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Khoury JD
Curr Hematol Malig Rep; 2018 Dec; 13(6):477-483. PubMed ID: 30350260
[TBL] [Abstract][Full Text] [Related]
14. [Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine].
Sukegawa S; Sakata-Yanagimoto M; Matsuoka R; Momose H; Kiyoki Y; Noguchi M; Nakamura N; Watanabe R; Fujimoto M; Yokoyama Y; Nishikii H; Kato T; Kusakabe M; Kurita N; Obara N; Hasegawa Y; Chiba S
Rinsho Ketsueki; 2018; 59(12):2567-2573. PubMed ID: 30626790
[TBL] [Abstract][Full Text] [Related]
15. Germline missense NF1 mutation in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm.
Szczepaniak A; Machnicki M; Gniot M; Pępek M; Rydzanicz M; Płoski R; Kaźmierczak M; Stokłosa T; Lewandowski K
Int J Hematol; 2019 Jul; 110(1):102-106. PubMed ID: 30977107
[TBL] [Abstract][Full Text] [Related]
16. Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics.
Sapienza MR; Pileri S
Hematol Oncol Clin North Am; 2020 Jun; 34(3):511-521. PubMed ID: 32336416
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP.
Li M; Shah M; Binder M; Lasho T; Carr R; Mangaonkar A; Gangat N; Coltro G; Tefferi A; Dao L; Peters M; Chiu A; Patnaik MM
Am J Hematol; 2020 Feb; 95(2):E31-E34. PubMed ID: 31705546
[No Abstract] [Full Text] [Related]
18. Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations.
Kurt H; Khoury JD; Medeiros LJ; Huh YO
Br J Haematol; 2018 May; 181(3):305. PubMed ID: 29411884
[No Abstract] [Full Text] [Related]
19. TET2 mutation as prototypic clonal hematopoiesis lesion.
Guarnera L; Jha BK
Semin Hematol; 2024 Feb; 61(1):51-60. PubMed ID: 38431463
[TBL] [Abstract][Full Text] [Related]
20. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Beird HC; Khan M; Wang F; Alfayez M; Cai T; Zhao L; Khoury J; Futreal PA; Konopleva M; Pemmaraju N
Blood Cancer J; 2019 Dec; 9(12):99. PubMed ID: 31811114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
